Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect on Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis in Patients With Type 2 Diabetes Mellitus on Treatment With Gastric Inhibitory Polypeptide / Glucagon Like Peptide-1 Analogue (Tirzpatide)

NCT05751720 is registered in ClinicalTrials.gov with Dr Adnan Agha as lead sponsor.

NCT NCT05751720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05751720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect on Non-Alcoholic Fatty Liver Disease With Advanced Fibrosis in Patients With Type 2 Diabetes Mellitus on Treatment With Gastric Inhibitory Polypeptide / Glucagon Like Peptide-1 Analogue (Tirzpatide)
Lead sponsor
Dr Adnan Agha
Phase
Phase 1/2
Overall status
Unknown status
Start date
October 1, 2023
Completion date
February 28, 2025
Enrollment
30 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver fat, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, type 2 diabetes